WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer 05 June 2017
Array BioPharma and Bristol-Myers Squibb announce strategic collaboration 30 May 2017
Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds 13 April 2017
The first overall survival data from the Phase 3 CheckMate -067 clinical trial 03 April 2017
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute announce collaboration to accelerate immuno-oncology research 28 March 2017
Bristol-Myers Squibb expands focus on precision medicine with investment and planned collaboration with GRAIL 02 March 2017
Bristol-Myers Squibb expands International Immuno-Oncology Network (II-ON) 27 February 2017
Bristol-Myers Squibb appoints three new independent directors 21 February 2017
Bristol-Myers Squibb reports fourth quarter and full year 2016 financial results 26 January 2017
Bristol-Myers Squibb and GeneCentric Diagnostics announce exploratory biomarker research collaboration 10 January 2017
Bristol-Myers Squibb announces immunotherapy clinical collaboration with Janssen 05 January 2017
Bristol-Myers Squibb signs exclusive worldwide license agreement with PsiOxus Therapeutics 20 December 2016
Bristol-Myers Squibb strengthens capabilities with evolution of its U.S. geographic footprint 13 December 2016
Bristol-Myers Squibb reports third quarter results 27 October 2016
Bristol-Myers Squibb Foundation joins White House Cancer Moonshot 18 October 2016
Bristol-Myers Squibb and Nektar Therapeutics announce oncology clinical collaboration to evaluate the combination of Opdivo (nivolumab) and NKTR-214 27 September 2016
Bristol-Myers Squibb awards first "Golden Tickets" for LabCentral to PanTher, Suono Bio 20 September 2016
Bristol-Myers Squibb employees cycle Coast to Coast to raise money and awareness for cancer research 07 September 2016
Bristol-Myers Squibb reports second quarter financial results 29 July 2016
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals 05 July 2016
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.